253 related articles for article (PubMed ID: 21428919)
1. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Marshall G; Howard Z; Dry J; Fenton S; Heathcote D; Gray N; Keen H; Logie A; Holt S; Smith P; Guichard SM
Biochem Soc Trans; 2011 Apr; 39(2):456-9. PubMed ID: 21428919
[TBL] [Abstract][Full Text] [Related]
2. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin passes the torch: a new generation of mTOR inhibitors.
Benjamin D; Colombi M; Moroni C; Hall MN
Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
[TBL] [Abstract][Full Text] [Related]
5. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Chresta CM; Davies BR; Hickson I; Harding T; Cosulich S; Critchlow SE; Vincent JP; Ellston R; Jones D; Sini P; James D; Howard Z; Dudley P; Hughes G; Smith L; Maguire S; Hummersone M; Malagu K; Menear K; Jenkins R; Jacobsen M; Smith GC; Guichard S; Pass M
Cancer Res; 2010 Jan; 70(1):288-98. PubMed ID: 20028854
[TBL] [Abstract][Full Text] [Related]
6. mTOR as a therapeutic target in patients with gastric cancer.
Al-Batran SE; Ducreux M; Ohtsu A
Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
[TBL] [Abstract][Full Text] [Related]
7. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
8. Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines.
Zhang W; Khatibi NH; Yamaguchi-Okada M; Yan J; Chen C; Hu Q; Meng H; Han H; Liu S; Zhou C
Exp Neurol; 2012 Feb; 233(2):799-806. PubMed ID: 22177999
[TBL] [Abstract][Full Text] [Related]
9. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
Lv X; Ma X; Hu Y
Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
Sini P; James D; Chresta C; Guichard S
Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
[TBL] [Abstract][Full Text] [Related]
11. Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ; Pollak M; Sonenberg N
BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
13. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
14. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
15. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
Jiang Q; Weiss JM; Back T; Chan T; Ortaldo JR; Guichard S; Wiltrout RH
Cancer Res; 2011 Jun; 71(12):4074-84. PubMed ID: 21540234
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
17. Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells.
Chen Y; Tsai YH; Tseng BJ; Pan HY; Tseng SH
J Pediatr Surg; 2016 Nov; 51(11):1818-1825. PubMed ID: 27492819
[TBL] [Abstract][Full Text] [Related]
18. Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.
Mohindra NA; Platanias LC
Leuk Lymphoma; 2015; 56(9):2518-23. PubMed ID: 25747970
[TBL] [Abstract][Full Text] [Related]
19. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
[TBL] [Abstract][Full Text] [Related]
20. ATP-competitive inhibitors of mTOR: an update.
Schenone S; Brullo C; Musumeci F; Radi M; Botta M
Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]